Abstract:ObjectivesIn patients with systemic lupus erythematosus (SLE), immune tolerance breakdown leads to autoantibody production and immune-complex glomerulonephritis. This study aimed to identify pathogenic plasma cells (PC) in the development of lupus nephritis.MethodsPC subsets in peripheral blood and renal tissue of patients with SLE and lupus mice were examined by flow cytometry and confocal microscopy, respectively. Sorting-purified PCs from lupus mice were adoptively transferred into Rag2-deficient recipients, in which immune-complex deposition and renal pathology were investigated. In culture, PCs from lupus mice and patients with SLE were treated with a TLR4 inhibitor and examined for autoantibody secretion by enzyme-linked immunospot assay (ELISPOT). Moreover, lupus mice were treated with a TLR4 inhibitor, followed by the assessment of serum autoantibody levels and glomerulonephritis activity.ResultsThe frequencies of TLR4+CXCR4+ PCs in peripheral blood and renal tissue were found significantly increased with the potent production of anti-dsDNA IgG, which were associated with severe renal damages in patients with SLE and mice with experimental lupus. Adoptive transfer of TLR4+CXCR4+ PCs from lupus mice led to autoantibody production and glomerulonephritis development in Rag2-deficient recipients. In culture, TLR4+CXCR4+ PCs from both lupus mice and patients with SLE showed markedly reduced anti-dsDNA IgG secretion on TLR4 blockade. Moreover, in vivo treatment with TLR4 inhibitor significantly attenuated autoantibody production and renal damages in lupus mice.ConclusionsThese findings demonstrate a pathogenic role of TLR4+CXCR4+ PCs in the development of lupus nephritis and may provide new therapeutic strategies for the treatment of SLE.

Retinal Epithelial Fine Structure in the Domestic Cat (Felis catus)

Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus

Apoptotic Cell-Mimicking Gold Nanocages Loaded with LXR Agonist for Attenuating the Progression of Murine Systemic Lupus Erythematosus.

Novel Mitophagy Inducer Alleviates Lupus Nephritis by Reducing Myeloid Cell Activation and Autoantigen Presentation.

Mesenchymal stem cell therapy induces FLT3L and CD1c + dendritic cells in systemic lupus erythematosus patients

Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus

OX40L blockade cellular nanovesicles for autoimmune diseases therapy

Biomimetic liposomes hybrid with erythrocyte membrane modulate dendritic cells to ameliorate systemic lupus erythematosus

TLR4+CXCR4+ Plasma Cells Drive Nephritis Development in Systemic Lupus Erythematosus

Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus

Dexamethasone Loaded DNA Scavenger Nanogel for Systemic Lupus Erythematosus Treatment

Anti-CD19 CAR-T cell therapy for Systemic Lupus Erythematosus in a mouse disease model

Allogenic Umbilical Cord-Derived Mesenchymal Stromal Cells Sustain Long-Term Therapeutic Efficacy Compared with Low-Dose Interleukin-2 in Systemic Lupus Erythematosus.

Aberrant CD40-Induced NF-κB Activation in Human Lupus B Lymphocytes

CX-5461 ameliorates disease in lupus-prone mice by triggering B-cell ferroptosis via p53-SLC7A11-ALOX12 pathway

Red Blood Cell Membrane Functionalized Biomimetic Nanoparticles for Systemic Lupus Erythematosus Treatment

CD4+CD57+ senescent T cells as promoters of systemic lupus erythematosus pathogenesis and the therapeutic potential of senolytic BCL-2 inhibitor

A New Benzenediamine Derivative Modulates Toll-like Receptors-Induced Myeloid Dendritic Cells Activation and Ameliorates Lupus-Like Syndrome in MRLlpr/lpr Mice.

Blockade of OX40/OX40L signaling using anti‐OX40L alleviates murine lupus nephritis

A Benzenediamine Derivate FC-99 Attenuates Lupus Nephritis in MRL/lpr Mice Via Inhibiting Myeloid Dendritic Cell-Secreted BAFF

The Effect of Targeted Delivery of Anti-Tnf-α Oligonucleotide into CD169+ Macrophages on Disease Progression in Lupus-Prone MRL/lpr Mice.